Core Viewpoint - Zhuozheng Medical is undergoing its third submission for listing on the Hong Kong Stock Exchange, showing steady revenue growth and a turnaround to profitability, raising questions about its potential for a successful IPO [1][8] Company Performance - Zhuozheng Medical has experienced a compound annual growth rate (CAGR) of 42.4% in revenue from 2022 to 2024, with a 13.2% revenue increase in the first eight months of 2025 [1] - The company's gross margin improved from 9.3% to 24%, and net profit turned positive in 2024, with a 59.6% increase in net profit in the first eight months of 2025, leading to a net profit margin of 12% [1][5] - The company operates 19 medical service institutions in China, including 17 clinics and 2 hospitals, and has expanded to Singapore and Malaysia [2] Revenue Sources - The primary revenue source is from clinics, contributing 84.6% of total revenue, while hospital revenue has increased to 15.4% [2] - The company offers a range of medical services, with pediatric, dental, ophthalmology, dermatology, ENT, and surgery services accounting for over 80% of total revenue [2][4] Financial Health - As of September 2025, the company has cash and cash equivalents of only 88 million yuan, with total current assets of 147 million yuan, indicating limited cash flow [1] - The company has 2.326 billion yuan in convertible preferred stock liabilities, leading to a net liability gap of 2.082 billion yuan, which may necessitate equity conversion upon listing [1][5] Market Position - Zhuozheng Medical ranks third in total revenue among private high-end comprehensive medical service providers in China and first in terms of city coverage [1][6] - The company is strategically focused on first-tier cities, with significant revenue contributions from Shenzhen, Beijing, Guangzhou, Chengdu, and Wuhan, accounting for 76.7% of total revenue in the first eight months of 2025 [7] Industry Outlook - The private high-end comprehensive medical service sector in China is projected to grow at a CAGR of 22.8%, reaching 48.5 billion yuan in total revenue by 2024 and 96.5 billion yuan by 2029 [6] - The industry remains fragmented, with Zhuozheng Medical positioned to benefit from ongoing growth trends [6][7]

Core Viewpoint - Zhuozheng Medical is undergoing its third submission for an IPO on the Hong Kong Stock Exchange, showing steady revenue growth and a turnaround to profitability, raising questions about its potential for successful listing [1][7]. Financial Performance - The company has demonstrated a compound annual growth rate (CAGR) of 42.4% in revenue from 2022 to 2024, with a 13.2% revenue increase in the first eight months of 2025 [1]. - Gross profit margin has improved from 9.3% to 24%, and net profit is expected to turn positive in 2024, with a 59.6% increase in net profit in the first eight months of 2025, leading to a net profit margin of 12% [1][4]. - Cash and cash equivalents were only 88 million yuan as of September 2025, with total current assets at 147 million yuan, indicating limited cash flow [1]. Business Operations - Zhuozheng Medical operates 19 medical service institutions in China, including 17 clinics and 2 hospitals, and has expanded to Singapore and Malaysia [2]. - The majority of revenue comes from clinics (84.6%), while hospital revenue has increased to 15.4% [2]. - The company offers a membership plan that has significantly increased patient retention, with 52.43 million visits attributed to members in the first eight months of 2025 [4]. Market Position - Zhuozheng Medical ranks third in total revenue among private high-end comprehensive medical service providers in China and first in terms of city coverage [1][6]. - The company is concentrated in first-tier cities, with significant revenue contributions from Shenzhen, Beijing, Guangzhou, Chengdu, and Wuhan, accounting for 76.7% of total revenue [6]. Industry Outlook - The private high-end comprehensive medical service sector in China is expected to grow from 48.5 billion yuan in 2024 to 96.5 billion yuan by 2029, with a CAGR of 14.8% [4]. - The market is highly fragmented, with Zhuozheng Medical ranking second in patient visits, closely trailing the leader [6]. Challenges - The company faces challenges related to its convertible preferred shares, which significantly impact profit volatility, with 2.326 billion yuan in convertible preferred shares constituting 86% of current liabilities [4]. - The need for capital to support further expansion into new cities is critical, given the current cash constraints [6].

Core Viewpoint - Zhuozheng Medical Holdings Limited is advancing its IPO process on the Hong Kong Stock Exchange, focusing on the high-end medical service market targeting affluent consumers in major Chinese cities [2]. Group 1: Company Overview - Established in 2012, Zhuozheng Medical specializes in high-end medical services, targeting affluent consumers who prefer personalized healthcare [2]. - The company operates 19 medical service institutions in China, including 17 clinics and 2 hospitals, and has additional clinics in Singapore and Malaysia [2]. Group 2: Market Position - Zhuozheng Medical ranks first in the number of cities covered and second in the number of paid patient visits among private high-end comprehensive medical service groups in China as of 2024 [2]. Group 3: Customer Satisfaction and Marketing - The company relies on patient satisfaction for marketing, with a net promoter score increasing from 81.1 in 2022 to 87.6 in the first eight months of 2024 [3][4]. - Zhuozheng Medical has a membership base of 116,542 as of August 31, 2025, with renewal rates rising from 42% in 2022 to 67% in 2024 [4]. Group 4: Financial Performance - Zhuozheng Medical's revenue grew from 473 million yuan in 2022 to 690 million yuan in 2023, reaching 959 million yuan in 2024, with 696 million yuan reported in the first eight months of 2025 [4]. - The company achieved profitability in 2024, with an adjusted net profit of approximately 10.45 million yuan in the first eight months of 2025 [5]. Group 5: Investment and Use of IPO Proceeds - Major investors include Tencent, which holds a 19.39% stake, making it the largest institutional investor [6]. - The net proceeds from the IPO will be used for developing a medical AI talent pool, upgrading existing facilities, establishing new institutions, and potential acquisitions in first-tier and new first-tier cities [6].

Group 1 - The core point of the article is that Zhuozheng Medical Holdings Limited has submitted an application for listing on the Hong Kong Stock Exchange, with Haitong International and Pudong Development Bank International as joint sponsors [1] - Zhuozheng Medical was previously reported to have submitted listing applications on May 16, 2024, and March 18, 2025 [1] - According to Frost & Sullivan, Zhuozheng Medical is the third largest private mid-to-high-end comprehensive medical service provider in China, with a market share of 2% based on 2024 revenue [1] Group 2 - The company ranks first and second among all private mid-to-high-end comprehensive medical service groups in terms of the number of cities covered in China and the number of paid patient visits in 2024, respectively [1]

Group 1 - The core point of the article is that Zhuozheng Medical Holdings Limited has submitted a listing application to the Hong Kong Stock Exchange, with Haitong International and Ping An International as joint sponsors [1] - Zhuozheng Medical is the third largest private mid-to-high-end comprehensive medical service provider in China, with a market share of 2% based on projected revenue for 2024 [1] - The company ranks first and second among all private mid-to-high-end comprehensive medical service groups in terms of the number of cities covered in China and the number of paid patient visits in 2024, respectively [1]

中国第三大私立中高端综合医疗服务机构。 本文为IPO早知道原创 作者｜Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，卓正医疗控股有限公司（以下简称"卓正医疗"）于2025年3月18日更新招股 书，继续推进港交所主板上市进程，海通国际和浦银国际担任联席保荐人。 成立于2012年的卓正医疗作为一家私立中高端综合医疗服务机构，专注于服务中高端医疗服务市 场。截至2025年3月10日已在深圳、广州、北京、成都、苏州、长沙、上海、重庆、杭州和武汉等 部分中国经济最发达的城市拥有并经营20家医疗服务机构，包括18家诊所和两家医院。截至同日， 卓正医疗还在新加坡开设了三家全科诊所。 根据弗若斯特沙利文的资料，以2023年收入 计算 ，卓正医疗是中国第三大私立中高端综合医疗服 务机构 ； 按截至2023年12月31日所覆盖的中国城市数量 和 2023年的付费患者就诊人次 计算 ， 卓正医疗在所有私立中高端综合医疗服务机构集团中分别排名第一 和 第二。 在业务模式上，为不断提高从诊前咨询到随访整个过程的服务便利性和可及性，卓正医疗联动了医疗 服务机构和线上医疗服务平台。2022年至2024年，卓 ...